| Dr Tina R Melendrez-chu, MD | |
|
1441 Kapiolani Blvd Fl 16, Honolulu, HI 96814-4402 | |
| (808) 432-7600 | |
| Not Available |
| Full Name | Dr Tina R Melendrez-chu |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 1441 Kapiolani Blvd Fl 16, Honolulu, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184833022 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 8765 (Hawaii) | Primary |
| Entity Name | Hawaii Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710945969 PECOS PAC ID: 7618880667 Enrollment ID: O20031106000625 |
News Archive
The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Aviana Molecular Technologies, an Orlando-based company with technology developed at the University of Central Florida.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.
What we see in the periphery, just outside the direct focus of the eye, may sometimes be a visual illusion, according to new findings published in Psychological Science, a journal of the Association for Psychological Science.
A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tina R Melendrez-chu, MD 1441 Kapiolani Blvd Fl 16, Honolulu, HI 96814-4402 Ph: (808) 432-7600 | Dr Tina R Melendrez-chu, MD 1441 Kapiolani Blvd Fl 16, Honolulu, HI 96814-4402 Ph: (808) 432-7600 |
News Archive
The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Aviana Molecular Technologies, an Orlando-based company with technology developed at the University of Central Florida.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.
What we see in the periphery, just outside the direct focus of the eye, may sometimes be a visual illusion, according to new findings published in Psychological Science, a journal of the Association for Psychological Science.
A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.
› Verified 1 days ago
Sohee Ki, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 4, Honolulu, HI 96813 Phone: 808-586-2903 | |
Dr. Robert C. Pedersen, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2828 Paa St, Honolulu, HI 96819 Phone: 808-432-5777 | |
Dr. David H.f. Tom, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1100 Ward Ave, Suite 840, Honolulu, HI 96814 Phone: 808-522-4521 Fax: 808-522-3526 | |
Dr. Beau K. Nakamoto, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 888 S King St, Honolulu, HI 96813 Phone: 808-522-4000 Fax: 808-522-4437 | |
Dr. Christina S Hines, MD., PH.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 459 Patterson Rd, Honolulu, HI 96819 Phone: 808-433-0320 | |
Daniel A. Alicata, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1356 Lusitana St, 4th Floor, Honolulu, HI 96813 Phone: 808-586-2900 | |
Angela Hu, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 4, Honolulu, HI 96813 Phone: 808-586-2903 |